Open access
Oct 2026
Hypoxia-inducible CEA-targeted CAR T-cell therapy for relapsed stage IV non-small cell lung cancer.
A hypoxia-inducible CAR-T-cell product targeting carcinoembryonic antigen (CEA) that restricts CAR activation to hypoxic tumor niches via oxygen-dependent expression control is developed that provides clinical proof-of-concept for hypoxia-inducible CAR design and inform the rational development of strategies leveraging...
Shuang Wei, Jia-Qi Guo, Xue-Li Bai et al.
· Cancer Discovery · 0 citations